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Oseltamivir 
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Inﬂ  uenza A 
Viruses (H1N1), 
South Africa 
To the Editor: Oseltamivir is the 
most widely used antiviral drug for 
inﬂ   uenza; it is a potent inhibitor of 
inﬂ   uenza virus neuraminidase (NA) 
protein (1). Until recently, oseltamivir 
resistance occurred in <1% of circu-
lating viruses globally. An increased 
number of inﬂ  uenza A viruses (H1N1) 
with resistance to oseltamivir was ﬁ  rst 
reported to the World Health Orga-
nization (WHO) by Norway in late 
January 2008. The viruses carried a 
speciﬁ  c histidine-to-tyrosine mutation 
at position 274 (H274Y; H275Y in N1 
numbering system) in the NA protein 
that confers high-level resistance to 
oseltamivir (2). Further surveillance 
by the European Surveillance Network 
for Vigilance against Viral Resistance 
and the WHO Global Inﬂ  uenza Sur-
veillance Network (GISN) showed 
that 16% of community isolates (0%–
67% by country) of inﬂ  uenza A virus-
es (H1N1) circulating in the 2007–08 
season in several other countries were 
also oseltamivir resistant (3). The pre-
dominant inﬂ  uenza subtype circulat-
ing in South Africa this winter season 
is H1N1. To determine whether oselta-
mivir-resistant viruses have spread to 
South Africa, we examined inﬂ  uenza 
A (H1N1) isolated during the 2008 
winter season for resistance to this an-
tiviral compound.
Specimens were obtained mainly 
from the National Institute of Com-
municable Diseases (NICD) active 
sentinel surveillance program in all 9 
provinces. Throat or nasopharyngeal 
swabs were taken from patients within 
48–72 hours of onset of symptoms and 
sent to NICD laboratories for virus 
isolation as described (4).
Of the H1N1 subtype viruses iso-
lated in May and June, 23 were sent 
to the WHO Collaborating Centers for 
Reference and Research on Inﬂ  uenza 
in London and Melbourne for resis-
tance testing (5,6). Forty-ﬁ  ve of the vi-
ruses, which included viruses isolated 
in July, were tested at NICD by using 
a modiﬁ  ed  ampliﬁ  cation  refractory 
mutation system PCR (ARMS-PCR) 
(7). This method can simultaneously 
detect wild-type or mutant virus with 
the 274 mutation in a single PCR. Par-
tial sequencing of the NA and hemag-
glutinin (HA) genes was performed to 
conﬁ  rm the NA H274Y resistance mu-
tation and to determine genetic drift 
in HA from the A/Brisbane/59/2007 
virus recommended for the Northern 
Hemisphere 2007–08 vaccine.
At the time of resistance testing, 
92 H1N1 subtype viruses had been 
isolated. The 23 virus isolates sent to 
the WHO Collaborating Centers were 
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highly resistant to oseltamivir by the 
NA inhibition enzyme assay, with 50% 
inhibitory concentration values of 
554 nM to 1,485 nM (A. Hay, I. Barr, 
pers. comm.). All 45 isolates tested 
locally were positive by ARMS-PCR 
for oseltamivir resistance at position 
274. The H274Y mutation was con-
ﬁ   rmed by sequence analysis of the 
N1 genes. The N1 sequences were 
closely related to those isolated in 
Europe and elsewhere in the 2007–08 
winter season. However, the presence 
of 1 or 2 aa mutations in viruses from 
South Africa (M23L and N73K in the 
stalk region) compared with resistant 
European isolates indicated that some 
genetic drift of N1 from the older 
strains had occurred. Although most 
2008 isolates were closely related to 
the A/Brisbane/59/2007 strain, sev-
eral of the isolates from South Africa 
had mutations in an additional 2 or 
3 aa residues at positions 183, 185, 
and 189, which mapped close to the 
receptor binding site of HA. (Gen-
Bank accession nos. for nucleotide 
sequences obtained in this study are 
EU914901–EU914916.)
Before the 2007–08 Northern 
Hemisphere winter, surveillance by 
GISN laboratories showed that oselta-
mivir-resistant H1N1 subtype viruses 
were extremely rare. Low numbers 
of drug-resistant viruses carrying the 
H274Y mutation usually followed 
oseltamivir treatment and showed re-
duced ﬁ  tness with poor transmission 
(8). Consequently, ﬁ  tter  nonresistant 
viruses appear to have predominated. 
In contrast, no evidence indicated that 
persons from whom resistant viruses 
were isolated during the European 
2007–08 winter season had either been 
treated or been in close contact with 
another person who had been treated 
with oseltamivir (2,8).
We report oseltamivir-resistant 
H1N1 subtype viruses in Africa and the 
Southern Hemisphere. It appears that 
resistant viruses have spread from the 
Northern Hemisphere and have under-
gone extensive transmission within the 
population. These viruses may soon ap-
pear in other countries in the Southern 
Hemisphere. Ongoing monitoring is 
needed to understand the further evolu-
tion of oseltamivir resistance.
Clinical symptoms of all patients 
in this study suggest an illness simi-
lar to that generally associated with 
seasonal inﬂ   uenza A virus (H1N1); 
no complications were reported. This 
ﬁ  nding is not unexpected because all 
isolates tested in the study were from 
outpatients. The policy in South Africa 
for use of oseltamivir for treatment of 
severe inﬂ   uenza remains unchanged 
because 2008 H3N2 subtype viruses 
are still drug sensitive.
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